Human studies · What the results mean
What have human studies found about Thymosin Alpha-1?
You’ll see which results held up and which didn’t. Each claim points to the paper behind it.
What do you need to know first about the drug?
Allan Goldstein’s team first took Thymosin Alpha-1 from a calf thymus. They wanted to learn how that gland helps your immune system. The compound is a peptide, a short chain of 28 protein parts called amino acids. That count helps you tell compounds apart. It doesn’t tell you whether one works. Doctors call the lab-made copy thymalfasin.
You may hear claims about hepatitis B, sepsis, COVID-19, cancer, and immune disease. The catch for you is that the studies don’t agree. The best human support is for long-term hepatitis B.
The largest sepsis trial found no survival gain [3].
Thymosin Alpha-1 isn’t a muscle or growth drug. Your body cuts it from a larger protein. It can alert some immune cells and quiet others. Think of a thermostat with heat and cooling. The United States hasn’t approved the drug for sale. About 35 other countries have [4]. You can also read what people noticed.
Which Thymosin Alpha-1 result looks strongest?
In 1977, Goldstein and his coworkers studied Thymosin Alpha-1 from calf thymus [1]. Its 28-amino-acid chain is made of small protein parts. Your body cuts that chain from a larger 113-amino-acid protein. The first part carries a small chemical change that the compound needs to work [1].
First, a hepatitis B review joined eight trials with 583 patients. Each trial lets you compare two types of care. One group got lamivudine, a pill that fights the virus. The other got lamivudine plus thymalfasin. A blood test showed a virus marker gone and a matching defense marker present in 45.1% of the two-drug group. The same change happened in 15.2% of the pill-only group [14].
That large gap is the clearest result for you to weigh.
Another review found better virus control and fewer returns of the virus [13]. The two-drug plan also gave better virus blood tests than entecavir, another virus pill, in people with liver scarring. Lab work found that Thymosin Alpha-1 can wake tired immune cells and quiet an overdone response [5]. You can read that work on the thymosin alpha 1 mechanism of action page.
Did the drug help people with sepsis live longer?
First, you need to know no other sepsis test was larger or more careful. The 2025 phase-3 TESTS trial enrolled 1,106 adults at 22 centers. Neither the adults nor their doctors knew who got Thymosin Alpha-1. The other group got a placebo, a shot with no drug. The trial compared each group’s 28-day death rate. The rates were 23.4% with the compound and 24.1% with placebo. Its 95% range tells you that either some help or some harm remained possible [3].
People who got the compound didn’t live longer.
An earlier trial had looked more hopeful. The 2013 ETASS report covered a 361-patient trial. Its 28-day death rates were 26.0% and 35.0%. That was about a 9-point gap. Yet the study left too much doubt to rule out chance [2]. The larger trial didn’t find the same benefit. For you, “studied” still doesn’t mean “proven.”
Which similar name means this drug?
First, Thymosin Alpha-1 and thymosin beta-4 are different drugs. You may see sellers call the repair drug “TB-500.” It has a 43-amino-acid chain made of small protein parts and is tied to tissue repair. Beta-4, not alpha-1, appears on sports drug watchlists.
An older lab study found opposite immune effects. Alpha-1 helped one group of immune cells grow. Beta-4 let another group hold them back [9].
Thymosin Alpha-1 also differs from thymulin, thymopentin, thymalin, and prothymosin alpha. The Thymosin Alpha-1 research page explains each name. You can find reported downsides under Thymosin Alpha-1 effects. The papers appear under Thymosin Alpha-1 references.